---
title: Biomarkers in Parkinsonian Syndromes
nct_id: NCT06501469
overall_status: RECRUITING
sponsor: "Non-profit organization for scientific research in Parkinson's disease and related disorders"
study_type: OBSERVATIONAL
primary_condition: Parkinson Disease
countries: Greece
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06501469.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06501469"
ct_last_update_post_date: 2024-07-17
last_seen_at: "2026-05-12T07:05:25.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Biomarkers in Parkinsonian Syndromes

**Official Title:** Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes

**NCT ID:** [NCT06501469](https://clinicaltrials.gov/study/NCT06501469)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Non-profit organization for scientific research in Parkinson's disease and related disorders
- **Collaborators:** Biomedical Research Foundation, Academy of Athens
- **Conditions:** Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Atypical Parkinsonism, Parkinsonism
- **Start Date:** 2022-03-23
- **Completion Date:** 2030-03-25
- **CT.gov Last Update:** 2024-07-17

## Brief Summary

This is a prospective observational study to identify biomarkers in parkinson syndromes. Patients with parkinsonian syndromes at the early stages of disease will be recruited and will be followed up until their established clinical diagnosis or for at least 5 years. In this population, imaging and wet biomarkers as well as clinical data will b systematically collected.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
IΙnclusion Criteria:

* Written informed consent, including consent to monitoring
* Patients with Parkinsonism and disease duration \< 2 years
* Patients with Parkinsonism and disease duration \> 2 years
* Healthy individuals without any neurological disease

Exclusion Criteria:

* Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide).
* Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism).
* Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm
* Other serious diseases that indicate a life expectancy of \<5 years.
* Active participation in other interventional clinical studies
```

## Primary Outcomes

- **Demographics** _(time frame: At enrolment)_ — Age, gender, education, origin, race
- **Family history** _(time frame: At enrolment)_ — Family history of Parkinson's, dementia, tremor, other movement disorders, other neurological disorders
- **Age** _(time frame: At enrolment)_ — Age at onset in years
- **Disease duration** _(time frame: At enrolment)_ — Disease duration in years
- **First motor symptom** _(time frame: At enrolment)_ — First motor symptom time of onset
- **First non-motor symptom** _(time frame: At enrolment)_ — First non-motor symptom time of onset
- **Side of onset** _(time frame: At enrolment)_ — Side of onset of first motor symptom
- **Staging** _(time frame: At enrolment and every six months over 5 years)_ — Hoehn and Yahr stage (H\&Y) stage (1-5, higher score indicate higher impairment)
- **Clinical scales - Unified Parkinson's disease rating scale (UPDRS)** _(time frame: At enrolment and every six months over 5 years)_ — Unified Parkinson's disease rating scale I-IV (UPDRS I-IV, 0-260; higher scores indicate higher impairment)
- **Clinical scales for Progressive supranuclear palsy (PSP)** _(time frame: At enrolment and every six months over 5 years)_ — Progressive supranuclear palsy rating scale (PSP-RS) (0-100; higher scores indicate higher impairment)
- **Clinical scales for Multiple system atrophy (MSA)** _(time frame: At enrolment and every six months over 5 years)_ — Unified Multiple system atrophy rating scale (UMSAPRS)(0-104; higher scores indicate higher impairment)
- **Clinical scales for PSP short** _(time frame: At enrolment and every six months over 5 years)_ — Progressive Supranuclear Palsy Clinical Deflicts Scale (PSP-CDS)(0-21; higher scores indicate higher impairment)
- **Clinical scales for apathy** _(time frame: At enrolment and every six months over 5 years)_ — Starkstein Apathy Scale (SAS) (0-56; higher scores indicate higher impairment)
- **Clinical scale for autonomic dysfunction** _(time frame: At enrolment and every six months over 5 years)_ — The Scale for Outcomes in Parkinson's disease for Autonomic symptoms - (0-100; higher scores indicate higher impairment)
- **Clinical scale for cognition** _(time frame: At enrolment and every six months over 5 years)_ — Montreal Cognitive Assessment (MOCA) (0-30, lower scores indicate higher impairment)
- **Clinical scale for frontal dysfunction** _(time frame: At enrolment and every six months over 5 years)_ — Frontal assessment battery (FAB) (0-18, lower scores indicate higher impairment)
- **Imaging outcome measures - nuclear medicine investigations** _(time frame: At enrolment)_ — (meta-iodobenzylguanidine) MIBG-Scintigraphy heart
- **Imaging outcome measures - Positron emission tomography (PET)** _(time frame: At enrolment)_ — fluorodeoxyglucose (FDG) -PET brain
- **Imaging outcome measures - Dopamine Transporters imaging (DaTScan)** _(time frame: At enrolment)_ — MRI brain
- **Imaging outcome measures - Magnetic resonance imaging (MRI)** _(time frame: At enrolment)_ — MRI brain
- **Blood samples analysis (DNA)** _(time frame: At enrolment)_ — Whole exome sequencing - genetic testing
- **Blood samples analysis (biomarkers, exosomes)** _(time frame: At enrolment and after 2 years)_ — Peripheral blood mononuclear cell (PBMCs), peripheral blood mononuclear cells, exosomes

## Locations (1)

- HYGEIA Hospital, Parkinson's disease and Movement Disorders Department, Athens, Greece — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hygeia hospital, parkinson's disease and movement disorders department|athens||greece` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06501469.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06501469*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*